Large description: Reactivity: The monoclonal antibody is directed against the CD13-antigen, which is expressed on human monocytes, granulocytes and their precursors and a small population of large granular lymphocytes. The monoclonal antibody reacts with monocytes, granulocytes and with a large number of acute myeloid leukaemia’s (the positivity of this marker relates to worse clinic prognosis).
Specificity: The CD13 antigen is an amnopeptidse N, 150 to 170 kDa sigle chain integral membrane protein. Present on the surface of early committed progenitors of granulocytes and monocytes (CFU-GM) and by all cells of these lineages as they mature. Expressed on endothelial cells, epithelial cells from renal proximal tubules and intestinal brush border, bone marrow stromal cells, osteoclasts, and cells lining bile duct canaliculi. Expressed on a small proportion of large granular lymphocytes (Soderberg et al 1993) but not other lymphocytes*
Present on monocytes and weakly expressed on granulocytes, it is only present on a small proportion of normal bone marrow cells and it is expressed on a small proportion of large granular lymphocytes (Soderberg et al 1993) but not other lymphocytes. These comprise a major portion of the normal granulocyte-macrophage progenitor population. CD13 is a type III glycoprotein, the extracellular region of which contains the catalytic unit of aminopeptidase-N which is a zinc binding metalloprotease..
Other names: Aminopeptidase N, Alanyl aminopeptidase, Aminopeptidase M, Microsomal aminopeptidase, Myeloid plasma membrane glycoprotein CD13, gp150
